Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says

On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that […]
Funding outlook shifts in fight against antimicrobial resistance

LONDON — Twenty-two research-based biopharmaceutical companies — including AstraZenica, GlaxoSmithKline and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR.
CAL02
BioVersys
Prevention of Post-Surgical Staphylococcal Infections.
SIRTURO® (bedaquiline) Development and Launch
BEAM Alliance – Guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field.
AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant
Leveraging global surveillance data to develop rapid diagnostics: MSD & OpGen’s Collaboration